Symposium New Treatments and Ethical Considerations
Prof Ceulemans nodigt ons uit voor het symposium New Treatments and Ethical Considerations op 9 november 2018.
Hoewel t snel is, is het programma zeer aanbevelingswaardig. Ik hoop dat u het kunt bezoeken!
vriendelijke groet, Herman Schippers penningmeester
It is our great pleasure to invite you to the autumn meeting of the Belgian Society of Pediatric Neurology which will take place in Flanders Meeting & Convention Center Antwerp - part of Elisabeth Center Antwerp, November 9th 2018.
“New Treatments and Ethical Considerations”
New treatments are becoming more and more available for neurometabolic, neuromuscular as well as epileptic disorders in children. However the cost of these treatments raises social questions and the discussion for whom these treatments must be available becomes a real ethical challenge for us pediatric neurologists.
With kind regards,
The team of Pediatric Neurology, University Hospital Antwerp and the BSPN board.
Participation fee all included
Please use the registration tool in the calendar section of our website www.bspn.be.
Registration will only be valid after payment of the participation fee, on a first paid first accepted basis. By bank transfer to the account number
IBAN : BE38 2100 0475 5072
BIC : GEBABEBB
using the account name “ASBL SOCIETE BELGE DE NEUROLOGIE PEDIATRIQUE”, and mentioning “BSPN Autumn Meeting 09/11/2018” and name of the participant
Trainee 25 €
BSPN member Free
Non-BSPN member 50€
On-Site registration 70€
Colleagues (especially trainees) are encouraged to submit a scientific abstract, preferably related to the theme of the day. Abstracts should be sent before October 15th , only by email to email@example.com Clearly indicate title, authors, address, and e-mail address. The abstract should be typed in MS-Word and not exceed 2000 characters.
Meeting language will be English Accreditation requested (Ethics and Economy)
Flanders Meeting & Convention Center Antwerp - part of Elisabeth Center Antwerp A room with a ZOO
Koningin Astridplein 20-26 │ 2018 Antwerp │ Belgium
Parking Station Zoo : Van Schoonhovestraat 25-27, 2060 Antwerpen
Q-Park Astridplein : Koningin Astridplein 41, 2018 Antwerpen (GPS : Gemeentestraat 32; 2018 Antwerpen)
Park & Ride
If you'd rather not drive and park in the busy Antwerp city centre, you can always use the Park & Ride formula: park easily and for free outside the city and hop on the tram or bus to the Flanders Meeting & Convention Center Antwerp. Find an overview of all the park & ride locations in the city on this website: www.slimnaarantwerpen.be.
By tram or bus
The Flanders Meeting & Convention Center Antwerp is located next to Antwerp Central Station. All information, timetables, and fares can be found on the NMBS website.
Over twenty tram and bus routes stop within 250 metres from the Flanders Meeting & Convention Center Antwerp.
Registration & coffee
Welcome: Berten Ceulemans and Gunnar Buyse
Chairs : An Jonckheere, Nicolas Deconinck
Lysosomal Diseases : Rare and expensive disorders?
François Eyskens, University Hospital Antwerp
Neurotransmitter disorders: Treatable at what cost?
Luc Régal, University Hospital Brussels
Autumn meeting of the Belgian Society of Pediatric Neurology Antwerp, November 9th 2018
New Treatments and Ethical Considerations
Chairs: Helene Verhelst, Marie-Cécile Nassogne
Refugees and Pediatric Neurology
Anne-Marie Hoogewys, Fedasil
“Neurology in the Zoo”
Francis Vercammen, veterinarian Zoo Antwerp
General Assembly BSPN Lunch
Chairs : Patricia Leroy, An Jansen
Cannabidiol & Everolimus: One hype and Specific?
Alec Aeby, University Hospital Reine Fabiola Brussels
Radiprodil & Fenfluramine: Brand New and a Revival?
An-Sofie Schoonjans, University Hospital Antwerp
Pharmacogenomics & Precise Medicine in epilepsy
Simona Balestrini, University College London
Chairs : Berten Ceulemans, Gunnar Buyse
Spinal Muscular Atrophy and Nusinersen (Spinraza®):
Nathalie Goemans, University Hospitals Leuven
The role of the neuropediatrician in the reimbursement process of orphan drugs.
Katrien De Groote (Innosens) Kris Schellens (Biogen) Francis Arickx (RIZIV/INAMI) Nathalie Goemans (UZL)
Closing remarks and reception